Is Latanoprost More Effective for Hair Regrowth than Minoxidil?

Hair loss is a shared concern that pushes many of us to look for treatments that are not only effective but also backed by credible research. Minoxidil has been in the spotlight for decades, while latanoprost is sometimes raised as a possible contender. The question is: when the published evidence is compared, is latanoprost truly more effective for hair regrowth than minoxidil?

One thing should be said at the start: no published trial has compared the two drugs head to head for scalp hair. What follows is a comparison of separate bodies of evidence, which is a weaker basis than a direct trial.

Minoxidil has the weight of FDA approval and more than three decades of clinical trials. Its mechanism is described as widening blood vessels in the scalp, which improves nutrient supply to hair follicles and may extend the anagen phase—the active growth stage of the hair cycle. In contrast, latanoprost is a prostaglandin analog, meaning it mimics chemical messengers that influence biological functions, including hair follicle activity. The drug was never developed for hair loss but for glaucoma. Patients using eye drops reported thicker, longer eyelashes, which raised questions about whether it could do the same for scalp hair. Researchers have since tried to put this observation to the test.

A Critical Look at Minoxidil Research

Minoxidil is often referred to as the standard topical hair loss treatment. But what does the evidence actually show? A 2002 trial by Olsen and colleagues enrolled 393 men with androgenetic alopecia and compared 5% topical minoxidil with 2% minoxidil and placebo over 48 weeks. The study used hair counts from marked areas of the scalp and photographic evaluations. The authors reported significant regrowth compared with placebo. However, not every participant responded, and scalp irritation was reported as a side effect. The trial is robust in terms of sample size and duration, but why only some individuals respond remains unexplained.

In 2004, Lucky and collaborators studied 381 women over 48 weeks, comparing 5% and 2% minoxidil solutions with placebo. Assessments were made through hair counts, standardized photography and investigator evaluations. The results supported the drug's activity in female pattern hair loss, yet the improvements were modest. Note that minoxidil products are labelled differently for women than for men in several markets, so which strength and formulation is appropriate is a question for a pharmacist or prescriber, not something to read off a trial. A separate and well-known point about minoxidil, reported in its labelling rather than as an endpoint of these two trials, is that hair gained is lost again after treatment stops. Minoxidil does not cure hair loss; it maintains a result for as long as application continues.

A Critical Look at Latanoprost Research

Latanoprost research, in comparison, is far less developed. Blume-Peytavi and colleagues conducted a 2012 pilot study in which 16 men with androgenetic alopecia applied 0.1% latanoprost or placebo for 24 weeks. Hair growth was assessed through photographic hair counts in defined scalp regions. The authors reported an increase in hair density in the latanoprost group. However, with only 16 participants and a short time frame, the study cannot claim broad validity. The 0.1% strength tested is also twenty times the concentration of the licensed 0.005% eye drop.

Further evidence comes from animal work. Sasaki and colleagues applied prostaglandin F2α and its analogues, latanoprost among them, to shaved mouse skin and reported earlier hair regrowth and effects on follicular pigment production compared with controls. While this supports a plausible biological mechanism, mouse hair cycles differ from human cycles, which makes direct application to humans questionable. Small scale, short duration, and lack of replication remain the main criticisms of latanoprost research for the scalp.

What the comparison supports

On the published evidence, minoxidil is the better-supported option. It has decades of research, multiple randomized controlled trials with hundreds of participants, and regulatory approval from the FDA for hair loss. Its weaknesses—limited responders, irritation, and the need for continuous use—are well documented, but they are at least documented.

Latanoprost, by contrast, remains experimental for the scalp. The published evidence is too limited to establish effectiveness there. Until large, long-term human trials are published, it is not scientifically sound to claim that latanoprost is more effective than minoxidil for scalp hair regrowth. At most it can be described as a possible future option that still requires proper testing.

In short: the minoxidil evidence is two large randomized trials (Olsen 2002 in men, Lucky 2004 in women) with hundreds of participants each, and the latanoprost scalp evidence is one 16-man pilot plus rodent work. The gap is in the size and quality of the evidence, not only in the results.

So...

Is latanoprost more effective for hair regrowth than minoxidil? Based on the current state of research, there is no evidence that it is. Minoxidil remains the better-evidenced option, with extensive data behind its use. Latanoprost may one day prove to be a useful alternative, but right now the evidence is preliminary. What the record shows is that minoxidil's effect is partial and requires ongoing use, but it is well documented, while latanoprost's effect on the scalp has not been demonstrated at a level that would support clinical use.

Minoxidil is available over the counter in many countries; latanoprost is a prescription eye drop and any scalp use of it is off-label. Talk to a doctor or pharmacist before starting, stopping or combining either treatment.

References

Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology, 66(5), 794–800. Retrieved from https://pubmed.ncbi.nlm.nih.gov/21875758/

Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., Savin, R. C., & Tharp, M. D. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 50(4), 541–553. Retrieved from https://pubmed.ncbi.nlm.nih.gov/15034503/

Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377–385. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12196747/

Sasaki, S., Hozumi, Y., & Kondo, S. (2005). Influence of prostaglandin F2α and its analogues on hair regrowth and follicular melanogenesis in a murine model. Experimental Dermatology, 14(5), 323–328. Retrieved from https://pubmed.ncbi.nlm.nih.gov/15854125/